Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Planting, A. S. T.
Right arrow Articles by Verweij, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Planting, A. S. T.
Right arrow Articles by Verweij, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:613-616, 1995
© 1995 European Society for Medical Oncology

brief-report

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma

A. S. T. Planting1,, M. E. L. van der Burg1, S. H. Goey1, J. H. M. ScheUens1, M. J. van den Bent2, M. de Boer-Dennert1, G. Stoter1 and J. Verweij1

1Department of Medical Oncology (Division of Experimental Chemotherapy and Pharmacology), Rotterdam Cancer Institute/Daniel den Hoed Kliniek Rotterdam, The Netherlands
2Department of Neurology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek Rotterdam, The Netherlands

Correspondence to: A.S.T. Planting, M.D. Rotterdam Cancer Institute Groene Hilledijk 301 3075 EA Rotterdam The Netherlands

BACKGROUND: In a previous phase II study with a dose-intensive weekly cisplatin schedule for six cycles, we observed a partial response in 5 of 14 patients with pleural mesothelioma. However, response duration was short (median 6 months). Since oral etoposide may theoretically be synergis-tic to cisplatin, we performed a phase II study with the combination of both drugs.

PATIENTS AND METHODS: Twenty-five chemo-naive patients with pleural mesothelioma were treated with cisplatin 70 mg/m2 days 1–8–15 and days 29–36–43 in combination with oral etoposide 50 mg days 1–15 and days 29–43. Patients with stable disease, or better, continued treatment with oral etoposide 50 mg/m2/day days 1–21 every 28 days.

RESULTS: All patients were evaluable for response and toxicity. Complete response was observed in one patient and partial responses in 5 patients (RR% 24%; 95% Cl: 10%–45%) for a median duration of 30 weeks. Twelve patients had stable disease. The response status never improved during maintenance treatment with oral etoposide. Most patients tolerated the regimen very well. Toxicity was mainly haema-tologic with leukocytopenia causing treatment delays in 8 patients. Ototoxicity grade 1 or 2 was observed in 8 patients, neurotoxicity grade 1 in 9 patients and nephrotoxicity grade 1 in 1 patient.

CONCLUSION: Frequently administered cisplatin in combination with oral etoposide has a moderate but definite activity in pleural mesothelioma

pleural mesothelioma, cisplatin, oral etoposide, dose-intensity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
D. H. Sterman, L. R. Kaiser, and S. M. Albelda
Advances in the Treatment of Malignant Pleural Mesothelioma
Chest, August 1, 1999; 116(2): 504 - 520.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.